{"id":60712,"date":"2025-12-05T17:23:05","date_gmt":"2025-12-05T11:53:05","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=60712"},"modified":"2025-12-06T12:10:46","modified_gmt":"2025-12-06T06:40:46","slug":"india-bioeconomy","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/editorial-analysis\/05-12-2025\/india-bioeconomy","title":{"rendered":"India\u2019s Bioeconomic Opportunity &amp; Future Potential"},"content":{"rendered":"\n<p><strong>Syllabus: GS3\/Economy; GS3\/ Environment<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>India\u2019s bioeconomy<\/strong> needs capital-market innovation, regulatory modernisation and strategic blend of innovation to<strong> <\/strong>achieve <strong>$1.2 trillion by 2047.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>About Bioeconomy&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>As per <strong>Food and Agriculture Organization (FAO<\/strong>), the <strong>bioeconomy is the production, utilization and conservation of biological resources<\/strong>, including related knowledge, science, technology, and innovation, to provide information, products, processes and services across all economic sectors aiming <strong>toward a sustainable economy.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Status of India\u2019s Bioeconomy<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India\u2019s bioeconomy has witnessed exponential growth, expanding <strong>16-fold in a decade<\/strong>, from <strong>$10 billion in 2014<\/strong> to <strong>over $165 billion in 2024<\/strong>, and it aims to contribute about <strong>$1.2 trillion by 2047.<\/strong><\/li>\n\n\n\n<li>As per the <strong>India BioEconomy Report 2024<\/strong>, the sector c<strong>ontributes 4.25% to India\u2019s GDP<\/strong>, signalling its rising centrality in national development.\n<ul class=\"wp-block-list\">\n<li>It has been fueled by <strong>advances in biotechnology, pharmaceuticals, agriculture, and bioenergy<\/strong>, supported by a growing startup ecosystem and government support.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>In Ethanol, India is now the<strong> third-largest producer of blended ethanol,<\/strong> with production almost tripling in five years, supporting both energy security and decarbonization efforts.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Sectors Driving the India\u2019s Bioeconomy<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma:<\/strong> India is already a <strong>global leader in generics and vaccines<\/strong>, and it is focusing on <strong>biologics, biosimilars, and personalized medicine.<\/strong><\/li>\n\n\n\n<li><strong>Agricultural Biotechnology:<\/strong> Innovations in crop genetics, biofertilizers, and precision farming can enhance food security and sustainability.<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img data-dominant-color=\"c2c1c8\" data-has-transparency=\"false\" style=\"--dominant-color: #c2c1c8;\" loading=\"lazy\" decoding=\"async\" width=\"696\" height=\"388\" src=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.48.52-PM.png\" alt=\"\" class=\"not-transparent wp-image-60717\" srcset=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.48.52-PM.png 696w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.48.52-PM-300x167.png 300w\" sizes=\"auto, (max-width: 696px) 100vw, 696px\" \/><\/figure>\n<\/div>\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bioenergy &amp; Biofuels:<\/strong> Bioethanol and biogas offer scalable alternatives to fossil fuels, with a push for clean energy<\/li>\n\n\n\n<li><strong>Industrial biotechnology:<\/strong> <strong>Enzymes, bioplastics, and green chemicals<\/strong> are gaining traction as eco-friendly industrial inputs.<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img data-dominant-color=\"cfdad1\" data-has-transparency=\"false\" loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"320\" src=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.49.54-PM-1024x320.png\" alt=\"\" class=\"not-transparent wp-image-60718\" style=\"--dominant-color: #cfdad1; aspect-ratio:3.093744604937561;width:610px;height:auto\" srcset=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.49.54-PM-1024x320.png 1024w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.49.54-PM-300x94.png 300w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.49.54-PM-768x240.png 768w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/Screenshot-2025-12-05-at-4.49.54-PM.png 1126w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<ul class=\"wp-block-list\">\n<li>India can build <strong>thousands of deep-tech start-ups<\/strong>, lead globally in <strong>mRNA, RNAi, gene therapy, biosimilars, and biologics<\/strong>, emerge as a <strong>preferred global hub<\/strong> for clinical research and bio-manufacturing, generate <strong>millions of high-value jobs<\/strong> under the <strong><em>BioE\u00b3<\/em><\/strong><strong> framework,<\/strong> and realise a <strong>$1.2 trillion bioeconomy by 2047<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>India\u2019s Push For Expanding Bioeconomic Architecture<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BioE3 Policy:<\/strong> The <a href=\"https:\/\/www.nextias.com\/ca\/current-affairs\/27-08-2024\/bioe3-policy\" data-type=\"link\" data-id=\"https:\/\/www.nextias.com\/ca\/current-affairs\/27-08-2024\/bioe3-policy\">BioE3 policy<\/a> (Biotechnology for Economy, Environment, Employment) acts as a unifying strategy to propel biomanufacturing, focusing on six domains\u2014ranging from bio-based chemicals to functional foods, carbon capture, precision biotherapeutics, climate-smart agriculture, and even marine\/space bio-research.<\/li>\n\n\n\n<li><strong>Other Key Measures: <\/strong>National Mission on Bioeconomy (2016), National Biopharma Mission, Bio-RIDE, BioNEST incubators, Global Biofuels Alliance &amp; National Biological Data Centre (NBDC).&nbsp;<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Hindrances to Reach $1.2 Trillion by 2047<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>India\u2019s Structural Bottleneck: <\/strong>India does <strong>not permit pre-revenue or research-stage biotech companies<\/strong> to list publicly. Consequently:\n<ul class=\"wp-block-list\">\n<li>Innovators rely heavily on <strong>private, risk-averse capital<\/strong>.<\/li>\n\n\n\n<li><strong>Valuations remain suppressed<\/strong>.<\/li>\n\n\n\n<li><strong>High-potential start-ups relocate abroad<\/strong>, seeking more supportive ecosystems.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Regulatory Inefficiencies:<\/strong> Cumbersome approval processes for biotech products delay innovation and commercialization.\n<ul class=\"wp-block-list\">\n<li>Lack of a single-window clearance system for biotech startups and research trials creates uncertainty.<\/li>\n\n\n\n<li><strong>First-in-Human (FIH)<\/strong> trial approvals take months. Each trial phase requires <strong>fresh Subject Expert Committee (SEC)<\/strong> review.<\/li>\n\n\n\n<li>CDSCO lacks <strong>scientific capacity<\/strong> to assess emerging modalities like <strong>mRNA, CRISPR, CAR-T, and gene therapies<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Limited Capital Market Access:<\/strong> Biotech startups struggle to raise early-stage and scale-up funding due to high R&amp;D risks and long gestation periods.\n<ul class=\"wp-block-list\">\n<li>India lacks a robust biotech IPO pipeline, unlike the US and China, where public markets actively support biotech innovation.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Fragmented Innovation Ecosystem:<\/strong> Weak industry-academia linkages hinder translational research and product development.\n<ul class=\"wp-block-list\">\n<li>Many innovations remain trapped in labs due to poor commercialization pathways and limited tech transfer infrastructure.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Inadequate Infrastructure:<\/strong> Shortage of biomanufacturing facilities, especially for biologics, diagnostics, and advanced therapeutics.<\/li>\n\n\n\n<li><strong>Policy and Coordination Gaps:<\/strong> Multiple ministries (Science &amp; Tech, Health, Agriculture, Environment) operate in silos, leading to policy fragmentation.\n<ul class=\"wp-block-list\">\n<li>Absence of a centralized bioeconomy mission or roadmap with measurable milestones hampers strategic alignment.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Suggestions For Achieving Bioeconomy $1.2 Trillion by 2047<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Reform: <\/strong>India\u2019s current drug-regulation system \u2014 led by <strong>CDSCO<\/strong> \u2014 remains <strong>slow, fragmented, and bureaucratic<\/strong>.\n<ul class=\"wp-block-list\">\n<li>Even with capital access, innovation will stagnate without <strong>regulatory speed and scientific clarity<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Need of Innovation &amp; Biotech Board: <\/strong>India urgently needs a <strong>dedicated listing board<\/strong> on the <strong>NSE and BSE<\/strong>, modelled on <strong>NASDAQ<\/strong>, <strong>STAR<\/strong>, and <strong>Hong Kong\u2019s Biotech Chapter<\/strong>.\n<ul class=\"wp-block-list\">\n<li>It could <strong>unlock domestic capital<\/strong>, draw <strong>global institutional investors<\/strong>, and become the <strong>financial engine of India\u2019s bioeconomy<\/strong>.<\/li>\n\n\n\n<li>Such a platform should:\n<ul class=\"wp-block-list\">\n<li>Allow <strong>pre-revenue and research-stage biotech listings<\/strong>.<\/li>\n\n\n\n<li>Enable <strong>IP-led companies<\/strong> to access patient capital.<\/li>\n\n\n\n<li>Attract <strong>global investors<\/strong> to India\u2019s science story.<\/li>\n\n\n\n<li>Encourage <strong>domestic scaling<\/strong> instead of foreign migration.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Focus on Innovation: <\/strong>Both capital-market reform and regulatory reform together can drive innovation that powers <strong>global biotech leadership<\/strong>. It needs:\n<ul class=\"wp-block-list\">\n<li>A <strong>dedicated Innovation &amp; Biotech Board<\/strong>;<\/li>\n\n\n\n<li>A <strong>science-led dual-agency regulatory system<\/strong>; and<\/li>\n\n\n\n<li>Strong <strong>institutional support<\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Two-Pillar Model for India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Empower ICMR for Scientific Review: <\/strong>ICMR\u2019s research depth and ethical infrastructure make it ideal for evaluating early-stage drugs, vaccines, diagnostics, and advanced biologics.<\/li>\n\n\n\n<li><strong>Position CDSCO as Licensing Authority: <\/strong>CDSCO should focus on final approvals, GMP compliance, site inspections, and pharmacovigilance.\n<ul class=\"wp-block-list\">\n<li><strong>Separation of scientific assessment (ICMR)<\/strong> and <strong>administrative licensing (CDSCO)<\/strong> could reduce approval timelines, improve scientific rigour, and reinforce investor confidence.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-background\" style=\"background-color:#ebecf0\"><tbody><tr><td><strong>Case Study of China<\/strong><br>&#8211; <strong>Capital Innovation Fuels Scientific Innovation:<\/strong><br>1. <strong>STAR Market (Shanghai, 2019):<\/strong> Enabled pre-revenue deep-tech firms to list without profitability requirements, mobilising <strong>$130+ billion<\/strong>.<br>2. <strong>Hong Kong Biotech Chapter (2018):<\/strong> Allowed non-revenue biotech IPOs; over <strong>70 companies listed<\/strong>, raising <strong>$25 billion<\/strong>.<br>3. <strong>Venture Capital Inflows (2018\u20132022):<\/strong> <strong>$45 billion<\/strong> in life sciences \u2014 nearly <strong>10 times India\u2019s inflows<\/strong>.<br>4. <strong>Pharma R&amp;D Investment:<\/strong> Surpassed <strong>$20 billion<\/strong>, compared to India\u2019s <strong>$3 billion<\/strong>.<br>&#8211; China faced <strong>regulatory hurdles, similar to India<\/strong>, a decade ago but acted decisively:<br>1. Reformed <strong>NMPA<\/strong> into a <strong>science-led regulator<\/strong>.<br>2. Introduced <strong>time-bound review pathways<\/strong>, cutting trial approval times by <strong>40\u201360%<\/strong>.<br>3. Allowed <strong>parallel review of trial phases<\/strong>.<br>4. <strong>Aligned with ICH<\/strong> global standards.<br>5. <strong>Fast-tracked advanced modalities<\/strong>, approving multiple CAR-T and gene therapies before Western counterparts.<br>&#8211; This <strong>regulatory agility<\/strong> created <strong>predictability<\/strong>, which built <strong>investor confidence<\/strong>, fueling China\u2019s biotech surge.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Conclusion<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India stands at a decisive juncture. We have <strong>the science, the talent, and the market<\/strong>. What remains is the <strong>courage to reform<\/strong>.<\/li>\n\n\n\n<li><strong>Capital-market innovation<\/strong> and <strong>regulatory modernisation<\/strong> must be treated as <strong>national priorities<\/strong>.\n<ul class=\"wp-block-list\">\n<li>India can evolve <strong>from the pharmacy of the world to the lab of the world<\/strong> \u2014 leading global biotech innovation, not just supplying it with bold action.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-background\" style=\"background-color:#fff2cc\"><tbody><tr><td><strong>Daily Mains Practice Question<\/strong><br><strong>[Q]<\/strong> Discuss the opportunities and challenges India faces in realizing its bioeconomic potential by 2047. What strategic initiatives and sectoral transformations are necessary to achieve this goal?<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><a href=\"https:\/\/www.thehindubusinessline.com\/opinion\/india-can-build-a-12-trillion-bioeconomy-by-2047\/article70358533.ece\" target=\"_blank\" rel=\"noopener\">Source: BL<\/a><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.nextias.com\/ca\/wp-content\/uploads\/2025\/12\/UPSC-Editorial-Analysis-5-December-2025.pdf\">Download PDF<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p><strong>Published on:<\/strong> 5th December, 2025<\/p>\n<p>\nIndia\u2019s bioeconomy needs capital-market innovation, regulatory modernisation and strategic blend of innovation toachieve $1.2 trillion by 2047.<\/p>\n","protected":false},"author":15,"featured_media":60723,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22],"tags":[],"class_list":["post-60712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial-analysis"],"acf":[],"jetpack_featured_media_url":"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/12\/bioeconomic.webp","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/60712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=60712"}],"version-history":[{"count":10,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/60712\/revisions"}],"predecessor-version":[{"id":60814,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/60712\/revisions\/60814"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media\/60723"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=60712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=60712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=60712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}